Implanted Cardioverter Defibrillator Articles & Analysis: Older
6 articles found
NewPace develops and patented the Implantable Subcutaneous String Defibrillator (ISSD™) which is the first, completely unitary and flexible, rechargeable, lifesaving implanted defibrillator. Its innovative, minimally invasive, shape introduces a new dimension in subcutaneous cardioverter ...
Click the links below to learn more about a specific condition: Atrial Septal Defect (ASD) Aortic Valve Stenosis (AVS) Coarctation of the Aorta (CoA) Complete Atrioventricular Canal defect (CAVC) d-Transposition of the Great Arteries Ebstein’s Anomaly Hypoplastic Left Heart Syndrome Interrupted Aortic Arch I-Transposition of the Great Arteries Patent Ductus Arteriosus (PDA) ...
Rani Therapeutics, a San Jose-based company developing a pill to replace medical injections, went public on Friday. According to S-1 filings, shares were estimated to price between $14 and $16 last week. On Friday, shares debuted slightly lower, around $11. Rani raised about $73 million in its debut. Rani’s debut comes amidst a flurry of IPO activity in therapeutics. In 2020, 71 ...
For patients who are at high risk of SCA (such as post-heart attack patients with low heart functionality), the ‘gold standard’ of care is the use of an implantable cardioverter defibrillator (ICD). Currently, there are two types of ICD devices on the market: transvenous ICD (TV-ICD) and subcutaneous ICD (S-ICD). ...
The use of a novel implantable string subcutaneous defibrillator (ISSD, Newpace) that has no can, and has been designed to be placed without the need for a surgical pocket, may allow improved patient compliance and aesthetics, is less invasive, and has optimal implantation time. ...
May 16, 2017 – A new study examines the effectiveness of the implantable subcutaneous string defibrillator (ISSD), a flexible, string-shaped and first-ever rechargeable implantable cardioverter-defibrillator (ICD). ...